^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ATM (ATM serine/threonine kinase)

    i
    Apply
    Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors (NCT05687136)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/07/2024
    Primary completion :
    08/31/2026
    Completion :
    08/31/2026
    ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18
    |
    ATM mutation • ARID1A mutation
    |
    peposertib (M3814) • tuvusertib (M1774)
    Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer (NCT05941520)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/23/2024
    Primary completion :
    08/23/2027
    Completion :
    09/01/2028
    TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2
    |
    TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    tamoxifen • acolbifene
    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    08/09/2021
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    HER-2 • TP53 • ATM • RAS • CD4
    |
    HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
    Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors (NCT04266912)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    03/17/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • ARID1A • BAP1 • MSH2 • CDK12 • ATRX • CHEK2 • SMARCB1 • RAD51 • FANCA • BRIP1 • RAD51C • CD4 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    Bavencio (avelumab) • berzosertib (M6620)
    Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors (PEPN2112) (NCT05071209)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/22/2021
    Primary completion :
    09/30/2024
    Completion :
    11/22/2025
    BRCA1 • BRCA2 • ATM • MSH2 • CDK12 • WT1 • ATRX • CHEK2 • RAD51 • FANCA • POLD1 • FOXO1 • XRCC2 • ATF1 • PAX3
    |
    PAX3-FOXO1 fusion
    |
    elimusertib (BAY 1895344)
    Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM) (NCT05222971)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2022
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (NCI-2018-01648) (NCT03682289)
    Phase 2
    Rahul Aggarwal
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    01/17/2019
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    MSI • ATM • ARID1A • UGT1A1
    |
    ATM mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    Niraparib in Patients With Pancreatic Cancer (NCT03601923)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    10/22/2024
    Initiation :
    08/22/2018
    Primary completion :
    09/30/2025
    Completion :
    02/28/2026
    BRCA1 • BRCA2 • ATM • CHEK2
    |
    ATM mutation • PALB2 mutation • CHEK2 mutation
    |
    Zejula (niraparib)
    A Study of Pembrolizumab and Olaparib for People with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy (SPORE) (NCT04666740)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    10/14/2024
    Initiation :
    12/18/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    Olaparib in Treating Patients With Stage IV Pancreatic Cancer (NCT02677038)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    10/01/2024
    Initiation :
    11/11/2016
    Primary completion :
    07/18/2022
    Completion :
    07/18/2022
    BRCA1 • ATM • HRD • BRCA • RAD51
    |
    HRD • ATM mutation • BRCA mutation
    |
    Lynparza (olaparib)
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)
    Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (D5330C00004) (NCT02264678)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    10/31/2014
    Primary completion :
    08/05/2026
    Completion :
    08/05/2026
    HER-2 • ATM • HRD • BRCA • RAD51C • RAD51D
    |
    HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation • RAD51 mutation
    |
    Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • ceralasertib (AZD6738) • saruparib (AZD5305)
    Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (NCT05033756)
    Phase 2
    Institut fuer Frauengesundheit
    Active, not recruiting
    Last update posted :
    05/07/2024
    Initiation :
    07/30/2022
    Primary completion :
    01/01/2025
    Completion :
    02/01/2026
    HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4
    |
    HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM) (NCT05338346)
    Phase 1
    Antengene Discovery Limited
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    07/08/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    BRCA1 • BRCA2 • ATM • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    TP53 mutation • FANCF mutation
    |
    ATG-018
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04657068)
    Phase 1/2
    Artios Pharma Ltd
    Recruiting
    Last update posted :
    04/03/2024
    Initiation :
    12/13/2020
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    ATM • HRD • BRCA
    |
    HRD • BRCA mutation
    |
    gemcitabine • irinotecan • ART0380
    I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) (NCT05986071)
    Phase 1/2
    Institut Paoli-Calmettes
    Not yet recruiting
    Last update posted :
    03/29/2024
    Initiation :
    05/01/2024
    Primary completion :
    04/01/2027
    Completion :
    10/15/2027
    HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1
    |
    HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation
    |
    fulvestrant • tuvusertib (M1774)
    Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES) (NCT04276376)
    Phase 2
    Gustave Roussy, Cancer Campus, Grand Paris
    Suspended
    Last update posted :
    03/26/2024
    Initiation :
    04/12/2019
    Primary completion :
    12/01/2024
    Completion :
    04/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • IL2 • RAD51D • BARD1 • NBN • RAD54L • DRD
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) (NCT02975934)
    Phase 3
    pharmaand GmbH
    Active, not recruiting
    Last update posted :
    03/20/2024
    Initiation :
    06/13/2017
    Primary completion :
    08/25/2022
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • ATM • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation
    |
    docetaxel • Xtandi (enzalutamide) • Rubraca (rucaparib) • abiraterone acetate
    Pancreatic Cancer Screening for At-risk Individuals (PancreasScan) (NCT05006131)
    Phase N/A
    Beth Israel Deaconess Medical Center
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/10/2020
    Primary completion :
    03/10/2027
    Completion :
    03/10/2028
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
    A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer (NCT05566574)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    09/30/2022
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    ATM
    |
    ATM mutation • ATM deletion
    |
    camonsertib (RP-3500)
    Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals (NCT06122896)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    11/21/2023
    Primary completion :
    10/31/2040
    Completion :
    10/31/2041
    TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH) (NCT03413995)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    02/09/2024
    Initiation :
    09/10/2018
    Primary completion :
    11/08/2023
    Completion :
    09/01/2024
    BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD50 • RAD51D • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC
    |
    CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation
    |
    Rubraca (rucaparib)
    Pancreas Registry and High Risk Registry (NCT02775461)
    Phase N/A
    Icahn School of Medicine at Mount Sinai
    Recruiting
    Last update posted :
    01/30/2024
    Initiation :
    03/01/2013
    Primary completion :
    11/01/2033
    Completion :
    11/01/2033
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MSH2
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation
    NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (iRetroBC) (NCT06131424)
    Phase N/A
    AstraZeneca
    Not yet recruiting
    Last update posted :
    01/24/2024
    Initiation :
    03/04/2024
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation
    A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer (PLANETTE) (NCT04564027)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    12/14/2023
    Initiation :
    12/01/2020
    Primary completion :
    04/28/2023
    Completion :
    02/05/2024
    ATM
    |
    ATM mutation
    |
    ceralasertib (AZD6738)
    Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations (NCT03448718)
    Phase 2
    Matthew Galsky
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    04/17/2018
    Primary completion :
    07/14/2021
    Completion :
    10/15/2021
    BRCA1 • BRCA2 • ATM • POLE • ERCC2 • ATRX • BRCA • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • NBN • RAD54L • ERCC5 • FANCF • WRN • XRCC2 • ERCC4 • RAD52 • ERCC3 • FANCD2 • FANCE • FANCG • RECQL4 • FANCB • FANCC • XRCC3
    |
    Lynparza (olaparib)
    Radiation Therapy (RT) and Chemotherapy for the Treatment of Pancreatic Cancer With Homologous Recombination Deficiency That Has Spread to the Liver (NCT05182112)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    11/03/2023
    Initiation :
    12/20/2021
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    BRCA1 • BRCA2 • ATM • BAP1 • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • BARD1 • NBN • ABRAXAS1 • FANCC
    |
    BRCA1 mutation • PALB2 mutation
    |
    cisplatin • gemcitabine
    First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas (NCT03188965)
    Phase 2
    Bayer
    Completed
    Last update posted :
    10/11/2023
    Initiation :
    07/06/2017
    Primary completion :
    12/02/2022
    Completion :
    09/13/2023
    HER-2 • ER • PGR • ATM
    |
    ER positive • HR positive • HER-2 negative • PGR positive
    |
    elimusertib (BAY 1895344)
    Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer (NCT05013216)
    Phase 1
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    09/04/2023
    Initiation :
    04/11/2022
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1
    |
    KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation
    |
    Hiltonol (poly-ICLC) • KRAS peptide vaccine
    Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients (NCT01063517)
    Phase 2
    AstraZeneca
    Completed
    Last update posted :
    07/20/2023
    Initiation :
    02/02/2010
    Primary completion :
    05/11/2012
    Completion :
    06/29/2023
    ATM • HRD
    |
    Lynparza (olaparib) • paclitaxel
    Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk (NCT02478892)
    Phase N/A
    Abramson Cancer Center at Penn Medicine
    Recruiting
    Last update posted :
    07/19/2023
    Initiation :
    05/01/2015
    Primary completion :
    05/01/2025
    Completion :
    05/01/2027
    BRCA1 • BRCA2 • ATM • PALB2
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation
    M6620 (VX-970) in Selected Solid Tumors (NCT03718091)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    07/07/2023
    Initiation :
    01/08/2019
    Primary completion :
    06/01/2020
    Completion :
    07/08/2020
    BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
    |
    berzosertib (M6620)
    An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors (NCT01618136)
    Phase 1/2
    Eisai Limited
    Completed
    Last update posted :
    06/19/2023
    Initiation :
    01/01/2012
    Primary completion :
    07/01/2015
    Completion :
    07/01/2015
    HER-2 • ER • PGR • ATM
    |
    HER-2 negative
    |
    carboplatin • paclitaxel • temozolomide • stenoparib (2X-121)
    EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer (NCT05411679)
    Phase 2
    Ellipses Pharma
    Withdrawn
    Last update posted :
    06/12/2023
    Initiation :
    04/01/2023
    Primary completion :
    08/01/2024
    Completion :
    12/01/2024
    PD-L1 • ATM
    |
    ATM expression
    |
    Lynparza (olaparib) • davamotecan pegadexamer (EP0057)
    Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery (rtog 1005) (NCT01349322)
    Phase 3
    Radiation Therapy Oncology Group
    Active, not recruiting
    Last update posted :
    04/06/2023
    Initiation :
    05/01/2011
    Primary completion :
    01/25/2022
    ER • PGR • ATM • TGFB1
    |
    ATM mutation
    A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD) (NCT04985721)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    03/15/2023
    Initiation :
    02/24/2022
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    BRCA1 • BRCA2 • ATM • HRD • ARID1A • MSH2 • CDK12 • ATRX • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • FANCL • WRN • FANCI • FANCM • FANCG
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib)
    Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer (ProFam-Risk) (NCT05681416)
    Phase N/A
    Heinrich-Heine University, Duesseldorf
    Not yet recruiting
    Last update posted :
    01/12/2023
    Initiation :
    02/01/2023
    Primary completion :
    02/01/2026
    Completion :
    02/01/2027
    TP53 • BRCA1 • BRCA2 • KIT • ATM • MLH1 • MSH6 • MSH2 • PMS2 • EPCAM • HOXB13
    |
    PMS2 mutation
    The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer (NCT05461261)
    Phase 2
    The Affiliated Nanjing Drum Tower Hospital of N...
    Recruiting
    Last update posted :
    10/24/2022
    Initiation :
    07/01/2022
    Primary completion :
    06/30/2025
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • ATM • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL
    |
    cisplatin • carboplatin • docetaxel